PMID- 30333880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 16
IP  - 5
DP  - 2018 Nov
TI  - The role of protein p16(INK4a) in non-oropharyngeal head and neck squamous cell 
      carcinoma in Southern China.
PG  - 6147-6155
LID - 10.3892/ol.2018.9353 [doi]
AB  - Cyclin-dependent kinase inhibitor 2A (p16(INK4a)) protein is a surrogate 
      immunohistochemical marker of human papillomavirus infection in oropharynx 
      squamous cell carcinoma (OPSCC). However, the effects of p16(INK4a) in non-OPSCC 
      require additional analysis. In addition, major gaps remain in the literature, 
      including small volumes of data for China. Therefore, the present study evaluated 
      the frequency of p16(INK4a) positivity in patients with non-OPSCC in Southern 
      China, and assessed its prognostic value. p16(INK4a) expression status in 
      patients with non-OPSCC was determined by immunohistochemistry. 
      p16(INK4a)-positive expression was defined as a strong and diffuse staining in 
      >/=70% of the tumor cells. Then, the diagnostic value of p16(INK4a) in predicting 
      overall survival (OS) and disease-free survival (DFS) rate was determined. The 
      positive rate of p16(INK4a) was 26.3% in larynx cancer and 24.8% in oral cavity 
      cancer. Multivariate analysis revealed that the protein status independently 
      predicted improved OS rate, but not DFS rate (P=0.096). Comparing different 
      disease stages, patients at an early stage with p16(INK4a)-positive non-OPSCC 
      exhibited improved DFS and OS rates compared with those exhibited by patients who 
      were negative. The p16(INK4a)-positive rate in patients with non-OPSCC was 25.1% 
      [26.3% in Laryngeal squamous cell carcinoma (LSCC) and 24.8% in Oropharyngeal 
      squamous cell carcinomas (OSCC)] in the present cohort from South China. The 
      present study suggested that p16(INK4a) expression in non-OPSCC predicts 
      favorable clinical outcomes, particularly in early stage non-OPSCC and oral 
      cancer.
FAU - Yang, Hang
AU  - Yang H
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
FAU - Cao, Ye
AU  - Cao Y
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
AD  - Clinical Trial Center, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 
      510060, P.R. China.
FAU - Li, Zhi-Ming
AU  - Li ZM
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
FAU - Li, Ya-Jun
AU  - Li YJ
AD  - Department of Lymphoma and Hematology, Hunan Cancer Hospital, The Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, Hunan 410013, P.R. China.
AD  - Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya 
      School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China.
FAU - Jiang, Wen-Qi
AU  - Jiang WQ
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
FAU - Shi, Yan-Xia
AU  - Shi YX
AD  - Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of 
      Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180823
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6176411
OTO - NOTNLM
OT  - cyclin-dependent kinase inhibitor 2A expression
OT  - human papillomavirus infection
OT  - immunohistochemical marker
OT  - non-oropharynx squamous cell carcinoma
OT  - prognosis
EDAT- 2018/10/20 06:00
MHDA- 2018/10/20 06:01
PMCR- 2018/08/23
CRDT- 2018/10/19 06:00
PHST- 2016/05/05 00:00 [received]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2018/10/19 06:00 [entrez]
PHST- 2018/10/20 06:00 [pubmed]
PHST- 2018/10/20 06:01 [medline]
PHST- 2018/08/23 00:00 [pmc-release]
AID - OL-0-0-9353 [pii]
AID - 10.3892/ol.2018.9353 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Nov;16(5):6147-6155. doi: 10.3892/ol.2018.9353. Epub 2018 Aug 
      23.